FY2029 Earnings Estimate for BioAtla Issued By HC Wainwright

BioAtla, Inc. (NASDAQ:BCAB) – Equities research analysts at HC Wainwright issued their FY2029 earnings per share estimates for shares of BioAtla in a note issued to investors on Monday, March 31st. HC Wainwright analyst A. He expects that the company will post earnings of ($0.93) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for BioAtla’s current full-year earnings is ($1.46) per share.

BioAtla Stock Up 1.8 %

NASDAQ:BCAB opened at $0.35 on Wednesday. The stock has a market capitalization of $17.08 million, a price-to-earnings ratio of -0.21 and a beta of 1.19. BioAtla has a 52 week low of $0.24 and a 52 week high of $4.02. The firm has a 50 day moving average of $0.40 and a 200 day moving average of $1.10.

BioAtla (NASDAQ:BCAB) last announced its earnings results on Thursday, March 27th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.08.

Institutional Trading of BioAtla

Institutional investors have recently made changes to their positions in the business. XTX Topco Ltd boosted its holdings in BioAtla by 7.2% in the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock worth $273,000 after acquiring an additional 10,384 shares in the last quarter. Magnus Financial Group LLC acquired a new stake in BioAtla in the 4th quarter worth approximately $28,000. Norges Bank purchased a new stake in BioAtla during the 4th quarter worth approximately $230,000. Highbridge Capital Management LLC acquired a new position in BioAtla during the 4th quarter valued at approximately $1,484,000. Finally, Renaissance Technologies LLC raised its holdings in shares of BioAtla by 62.2% in the fourth quarter. Renaissance Technologies LLC now owns 829,596 shares of the company’s stock worth $490,000 after buying an additional 318,196 shares during the last quarter. Institutional investors and hedge funds own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.